GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
| Mar2021 | ₹-442 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | Negative | |
| Mar2021 | ₹-442 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹63,754.6 Cr | -3.5% | 0.8% | 66.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹442,725.0 Cr | -3.2% | 10.5% | 9.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹182,775.0 Cr | 0.8% | 9.5% | 4.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹151,764.0 Cr | 2% | 9.9% | 35.4% | Stock Analytics | |
| CIPLA | ₹113,007.0 Cr | -1.9% | 13.3% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹109,098.0 Cr | -1.8% | 7.4% | 8.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -3.5% |
0.8% |
66.2% |
| SENSEX | 0.2% |
-4.9% |
-8.4% |
You may also like the below Video Courses